Although the underlying molecular target(s) responsible for the antineoplastic activity of NSAIDs has been elusive as discussed below, the suppression of β-catenin mediated transcription by NSAIDs may provide a highly specific mechanism to compensate for the genetic aberrations that are associated with APC mutations, which are ultimately responsible for the initiation of colorectal cancer. Here, APC is linked to colorectal cancer.